A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis

Tomoko Takai, Katsumi Higaki, Matilde Aguilar-Moncayo, Teresa Mena-Barragán, Yuki Hirano, Kei Yura, Liang Yu, Haruaki Ninomiya, M. Isabel García-Moreno, Yasubumi Sakakibara, Kousaku Ohno, Eiji Nanba, Carmen Ortiz Mellet, José M. García Fernández, Yoshiyuki Suzuki

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Lysosomal β-galactosidase (β-Gal) deficiency causes a group of disorders that include neuronopathic GM1 gangliosidosis and non-neuronopathic Morquio B disease. We have previously proposed the use of small molecule ligands of β-Gal as pharmacological chaperones (PCs) for the treatment of GM1 gangliosidosis brain pathology. Although it is still under development, PC therapy has yielded promising preclinical results in several lysosomal diseases. In this study, we evaluated the effect of bicyclic 1-deoxygalactonojirimycin (DGJ) derivative of the sp2-iminosugar type, namely 5N,6S-(N′-butyliminomethylidene)-6-thio-1- deoxygalactonojirimycin (6S-NBI-DGJ), as a novel PC for human mutant β-Gal. In vitro, 6S-NBI-DGJ had the ability to inhibit the activity of human β-Gal in a competitive manner and was able to protect this enzyme from heat-induced degradation. Computational analysis supported that the rigid glycone bicyclic core of 6S-NBI-DGJ binds to the active site of the enzyme, with the aglycone N′-butyl substituent, in a precise E-orientation, located at a hydrophobic region nearby. Chaperone potential profiling indicated significant increases of enzyme activity in 24 of 88 β-Gal mutants, including four common mutations. Finally, oral administration of 6S-NBI-DGJ ameliorated the brain pathology of GM1 gangliosidosis model mice. These results suggest that 6S-NBI-DGJ is a novel PC that may be effective on a broad range of β-Gal mutants.

Original languageEnglish
Pages (from-to)526-532
Number of pages7
JournalMolecular Therapy
Volume21
Issue number3
DOIs
Publication statusPublished - 2013 Mar
Externally publishedYes

Fingerprint

GM1 Gangliosidosis
Pharmacology
Enzymes
Mucopolysaccharidosis IV
Galactosidases
Pathology
Brain
Human Activities
Oral Administration
Catalytic Domain
Hot Temperature
migalastat
Ligands
Mutation
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Takai, T., Higaki, K., Aguilar-Moncayo, M., Mena-Barragán, T., Hirano, Y., Yura, K., ... Suzuki, Y. (2013). A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Molecular Therapy, 21(3), 526-532. https://doi.org/10.1038/mt.2012.263

A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. / Takai, Tomoko; Higaki, Katsumi; Aguilar-Moncayo, Matilde; Mena-Barragán, Teresa; Hirano, Yuki; Yura, Kei; Yu, Liang; Ninomiya, Haruaki; García-Moreno, M. Isabel; Sakakibara, Yasubumi; Ohno, Kousaku; Nanba, Eiji; Ortiz Mellet, Carmen; García Fernández, José M.; Suzuki, Yoshiyuki.

In: Molecular Therapy, Vol. 21, No. 3, 03.2013, p. 526-532.

Research output: Contribution to journalArticle

Takai, T, Higaki, K, Aguilar-Moncayo, M, Mena-Barragán, T, Hirano, Y, Yura, K, Yu, L, Ninomiya, H, García-Moreno, MI, Sakakibara, Y, Ohno, K, Nanba, E, Ortiz Mellet, C, García Fernández, JM & Suzuki, Y 2013, 'A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis', Molecular Therapy, vol. 21, no. 3, pp. 526-532. https://doi.org/10.1038/mt.2012.263
Takai, Tomoko ; Higaki, Katsumi ; Aguilar-Moncayo, Matilde ; Mena-Barragán, Teresa ; Hirano, Yuki ; Yura, Kei ; Yu, Liang ; Ninomiya, Haruaki ; García-Moreno, M. Isabel ; Sakakibara, Yasubumi ; Ohno, Kousaku ; Nanba, Eiji ; Ortiz Mellet, Carmen ; García Fernández, José M. ; Suzuki, Yoshiyuki. / A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. In: Molecular Therapy. 2013 ; Vol. 21, No. 3. pp. 526-532.
@article{84e81945c11443e5aaf0f4cb32d3b9ca,
title = "A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis",
abstract = "Lysosomal β-galactosidase (β-Gal) deficiency causes a group of disorders that include neuronopathic GM1 gangliosidosis and non-neuronopathic Morquio B disease. We have previously proposed the use of small molecule ligands of β-Gal as pharmacological chaperones (PCs) for the treatment of GM1 gangliosidosis brain pathology. Although it is still under development, PC therapy has yielded promising preclinical results in several lysosomal diseases. In this study, we evaluated the effect of bicyclic 1-deoxygalactonojirimycin (DGJ) derivative of the sp2-iminosugar type, namely 5N,6S-(N′-butyliminomethylidene)-6-thio-1- deoxygalactonojirimycin (6S-NBI-DGJ), as a novel PC for human mutant β-Gal. In vitro, 6S-NBI-DGJ had the ability to inhibit the activity of human β-Gal in a competitive manner and was able to protect this enzyme from heat-induced degradation. Computational analysis supported that the rigid glycone bicyclic core of 6S-NBI-DGJ binds to the active site of the enzyme, with the aglycone N′-butyl substituent, in a precise E-orientation, located at a hydrophobic region nearby. Chaperone potential profiling indicated significant increases of enzyme activity in 24 of 88 β-Gal mutants, including four common mutations. Finally, oral administration of 6S-NBI-DGJ ameliorated the brain pathology of GM1 gangliosidosis model mice. These results suggest that 6S-NBI-DGJ is a novel PC that may be effective on a broad range of β-Gal mutants.",
author = "Tomoko Takai and Katsumi Higaki and Matilde Aguilar-Moncayo and Teresa Mena-Barrag{\'a}n and Yuki Hirano and Kei Yura and Liang Yu and Haruaki Ninomiya and Garc{\'i}a-Moreno, {M. Isabel} and Yasubumi Sakakibara and Kousaku Ohno and Eiji Nanba and {Ortiz Mellet}, Carmen and {Garc{\'i}a Fern{\'a}ndez}, {Jos{\'e} M.} and Yoshiyuki Suzuki",
year = "2013",
month = "3",
doi = "10.1038/mt.2012.263",
language = "English",
volume = "21",
pages = "526--532",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis

AU - Takai, Tomoko

AU - Higaki, Katsumi

AU - Aguilar-Moncayo, Matilde

AU - Mena-Barragán, Teresa

AU - Hirano, Yuki

AU - Yura, Kei

AU - Yu, Liang

AU - Ninomiya, Haruaki

AU - García-Moreno, M. Isabel

AU - Sakakibara, Yasubumi

AU - Ohno, Kousaku

AU - Nanba, Eiji

AU - Ortiz Mellet, Carmen

AU - García Fernández, José M.

AU - Suzuki, Yoshiyuki

PY - 2013/3

Y1 - 2013/3

N2 - Lysosomal β-galactosidase (β-Gal) deficiency causes a group of disorders that include neuronopathic GM1 gangliosidosis and non-neuronopathic Morquio B disease. We have previously proposed the use of small molecule ligands of β-Gal as pharmacological chaperones (PCs) for the treatment of GM1 gangliosidosis brain pathology. Although it is still under development, PC therapy has yielded promising preclinical results in several lysosomal diseases. In this study, we evaluated the effect of bicyclic 1-deoxygalactonojirimycin (DGJ) derivative of the sp2-iminosugar type, namely 5N,6S-(N′-butyliminomethylidene)-6-thio-1- deoxygalactonojirimycin (6S-NBI-DGJ), as a novel PC for human mutant β-Gal. In vitro, 6S-NBI-DGJ had the ability to inhibit the activity of human β-Gal in a competitive manner and was able to protect this enzyme from heat-induced degradation. Computational analysis supported that the rigid glycone bicyclic core of 6S-NBI-DGJ binds to the active site of the enzyme, with the aglycone N′-butyl substituent, in a precise E-orientation, located at a hydrophobic region nearby. Chaperone potential profiling indicated significant increases of enzyme activity in 24 of 88 β-Gal mutants, including four common mutations. Finally, oral administration of 6S-NBI-DGJ ameliorated the brain pathology of GM1 gangliosidosis model mice. These results suggest that 6S-NBI-DGJ is a novel PC that may be effective on a broad range of β-Gal mutants.

AB - Lysosomal β-galactosidase (β-Gal) deficiency causes a group of disorders that include neuronopathic GM1 gangliosidosis and non-neuronopathic Morquio B disease. We have previously proposed the use of small molecule ligands of β-Gal as pharmacological chaperones (PCs) for the treatment of GM1 gangliosidosis brain pathology. Although it is still under development, PC therapy has yielded promising preclinical results in several lysosomal diseases. In this study, we evaluated the effect of bicyclic 1-deoxygalactonojirimycin (DGJ) derivative of the sp2-iminosugar type, namely 5N,6S-(N′-butyliminomethylidene)-6-thio-1- deoxygalactonojirimycin (6S-NBI-DGJ), as a novel PC for human mutant β-Gal. In vitro, 6S-NBI-DGJ had the ability to inhibit the activity of human β-Gal in a competitive manner and was able to protect this enzyme from heat-induced degradation. Computational analysis supported that the rigid glycone bicyclic core of 6S-NBI-DGJ binds to the active site of the enzyme, with the aglycone N′-butyl substituent, in a precise E-orientation, located at a hydrophobic region nearby. Chaperone potential profiling indicated significant increases of enzyme activity in 24 of 88 β-Gal mutants, including four common mutations. Finally, oral administration of 6S-NBI-DGJ ameliorated the brain pathology of GM1 gangliosidosis model mice. These results suggest that 6S-NBI-DGJ is a novel PC that may be effective on a broad range of β-Gal mutants.

UR - http://www.scopus.com/inward/record.url?scp=84875223589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875223589&partnerID=8YFLogxK

U2 - 10.1038/mt.2012.263

DO - 10.1038/mt.2012.263

M3 - Article

C2 - 23337983

AN - SCOPUS:84875223589

VL - 21

SP - 526

EP - 532

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -